Pharmacodynamics of immunosuppression by mycophenolic acid: Inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics

Journal of Pharmacology and Experimental Therapeutics

Volumn 291, Issue 3, 1999, Pages 1100-1112

  Gummert, Jan F ^a   Barten, Markus J ^a   Sherwood, Steve W ^a   Van Gelder, Teun ^a   Morris, Randall E ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR; MYCOPHENOLIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; IMMUNOSUPPRESSIVE TREATMENT; INHIBITION KINETICS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD27; CELL DIVISION; DNA; FLOW CYTOMETRY; HEMATOCRIT; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTE COUNT; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MYCOPHENOLIC ACID; RATS; RATS, INBRED LEW; RECEPTORS, IMMUNOLOGIC; RECEPTORS, INTERLEUKIN-2; RECEPTORS, OX40; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 0032732954     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Allison AC, Almquist SJ, Muller CD and Eugui EM (1991) In vitro immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443. Transplant Proc 23:10-14.
2. Allison AC and Eugui EM (1994) Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation. Transplant Proc 26:3205-3210.
3. Allison AC and Eugui EM (1996) Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 10:77-84.
4. Bloemena E, Koopmans RP, Weinreich S, van Boxtel CJ and Schellekens PT (1990) Pharmacodynamic modeling of lymphocytopenia and whole blood lymphocyte cultures in prednisolone-treated individuals. Clin Immunol Immunopathol 57:374-386.
5. Brazelton TR and Morris RE (1996) Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: Tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr Opin Immunol 8:710-720.
6. Catapano CV, Dayton JS, Mitchell BS and Fernandes DJ (1995) GTP depletion induced by IMP dehydrogenase inhibitors blocks RNA-primed DNA synthesis. Mol Pharmacol 47:948-955.
7. Celis JE, Bravo R, Larsen PM and Fey SJ (1984) Cyclin: A nuclear protein whose level correlates directly with the proliferative state of normal as well as transformed cells. Leuk Res 8:143-157.
8. Cohen MB, Maybaum J and Sadee W (1981) Guanine nucleotide depletion and toxicity in mouse T lymphoma (S-49) cells. J Biol Chem 256:8713-8717.
9. Dayton JS, Turka LA, Thompson CB and Mitchell BS (1991) Guanine ribonucleotide depletion inhibits T cell activation. Adv Exp Med Biol 309:B293-B296.
10. Eugui EM, Almquist SJ, Muller CD and Allison AC (1991) Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: Role of deoxyguanosine nucleotide depletion. Scand J Immunol 33:161-173.
11. Fasanmade AA and Jusko WJ (1995) Optimizing whole blood lymphocyte proliferation in the rat. J Immunol Methods 184:163-167.
12. Franklin TJ and Cook JM (1969) The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 113:515-524.
13. Franklin TJ and Morris WP (1994) Pharmacodynamics of the inhibition of GTP synthesis in vivo by mycophenolic acid. Adv Enzyme Regul 34:107-117.
14. Fulton B and Markham A (1996) Mycophenolate mofetil: A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 51:278-298.
15. Gummert JF, Christians U, Barten M, Silva HT and Morris RE (1999a) A high-performance liquid chromatographic assay with a simple extraction procedure for sensitive quantification of mycophenolic acid in rat and human plasma. J Chromatogr B Biomed Appl 721:321-326.
16. Gummert JF, Otto G, Barten MJ and Morris RE (1999b) Effect of anesthesia on a whole blood lymphocyte proliferation assay in the rat. Immunopharmacol Immunotoxicol 21.
17. Kobashigawa JA, Miller L, Renlund DG, Mentzer RM Jr, Alderman E, Bourge RC, Costanzo M, Eisen H, Dureau G, Ratkovec R, Hummel M, Ipe D, Johnson J, Keogh A, Mamelok R, Mancini D, Smart F and Valantine H (1998) A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 66:507-515.
18. Langman LJ, Shapiro AM, Lakey JR, Le GD, Kneteman NM and Yatscoff RW (1996) Pharmacodynamic assessment of mycophenolic acid in a canine model. Transplant Proc 28:934-936.
19. Limbird LE (1996) Cell Surface Receptors: A Short Course on Theory and Methods, pp 79-82, Martinus Nijhoff Publishing, Boston.
20. Morris RE, Hoyt EG, Eugui EM and Allison AC (1989) Prolongation of rat heart allograft survival by RS-61443. Surg Forum 40:337-338.
21. Morris RE, Hoyt EG, Murphy MP, Eugui EM and Allison AC (1990) Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant Proc 22:1659-1662.
22. Morris RE and Wang J (1991) Comparison of the immunosuppressive effects of mycophenolic acid and the morpholinoethyl ester of mycophenolic acid (RS-61443) in recipients of heart allografts. Transplant Proc 23:493-496.
23. Morris RE, Wang J, Blum JR, Flavin T, Murphy MP, Almquist SJ, Chu N, Tam YL, Kaloostian M and Allison AC (1991) Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS-61443) in rat and nonhuman primate recipients of heart allografts. Transplant Proc 23:19-25.
24. Nowak I and Shaw LM (1995) Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 41:1011-1017.
25. Nowak I, Wu J, Brayman KL and Shaw LM (1997) Is the glucuronide metabolite of MPA pharmacologically active? Transplant Proc 29:337.
26. Ransom JT (1995) Mechanism of action of mycophenolate mofetil. Ther Drug Monit 17:681-684.
27. Shaw LM, Nicholls A, Hale M, Armstrong VW, Oellerich M, Yatscoff R, Morris RE, Holt DW, Venkataramanan R, Haley J, Halloran P, Ettenger R, Keown P and Morris RG (1998) Therapeutic monitoring of mycophenolic acid: A consensus panel report. Clin Biochem 31:317-321.
28. Shaw LM and Nowak I (1995) Mycophenolic acid: Measurement and relationship to pharmacologic effects. Ther Drug Monit 17:685-689.
29. Shaw LM, Sollinger HW, Halloran P, Morris RE, Yatscoff RW, Ransom J, Tsina I, Keown P, Holt DW and Lieberman R (1995) Mycophenolate mofetil: A report of the consensus panel. Ther Drug Monit 17:690-699.
30. Shifrine M, Taylor NJ, Rosenblatt LS and Wilson FD (1978) Comparison of whole blood and purified canine lymphocytes in a lymphocyte-stimulation microassay. Am J Vet Res 39:687-690.
31. Silva HT, Shorthouse R and Morris RE (1996) Single- and multiple-dose pharmacokinetics and pharmacodynamics of leflunomide's active metabolite A77 1726 in normal Lewis rats. Transplant Proc 28:3092-3094.
32. Sollinger HW (1995) Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients: U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 60:225-232.
33. Sugioka N, Koyama H, Ohta T, Kishimoto H, Yasumura T and Takada K (1996) Pharmacokinetics of mycophenolate mofetil, a new immunosuppressant, in rats. J Pharm Sci 85:335-338.
34. Taniguchi T and Minami Y (1993) The IL-2/IL-2 receptor system: A current overview. Cell 73:5-8.
35. Thompson SC, Bowen KM and Burton RC (1986) Sequential monitoring of peripheral blood lymphocyte subsets in rats. Cytometry 7:184-193.
36. Thomson AW, Woo J, Yao GZ, Todo S, Starzl TE and Zeevi A (1993) Effects of combined administration of FK 506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in human mixed lymphocyte cultures. Transpl Immunol 1:146-150.
37. Tittle TV, Weinberg AD, Steinkeler CN and Maziarz RT (1997) Expression of the T-cell activation antigen, OX-40, identifies alloreactive T cells in acute graft-veraus-host disease. Blood 89:4652-4658.
38. Weaver JL, Pine PS and Aszalos A (1991) Comparison of the in vitro and biophysical effects of cyclosporine A, FK-506, and mycophenolic acid on human peripheral blood lymphocytes. Immunopharmacol Immunotoxicol 13:563-576.
39. Williams RH, Lively DH, De LD, Cline JC and Sweeny MJ (1968) Mycophenolic acid: Antiviral and antitumor properties. J Antibiot (Tokyo) 21:463-464.
40. Wu JC (1994) Mycophenolate mofetil: Molecular mechanism of action. Perspect Drug Discovery Design 2:185-204.